Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China ...

Purpose: The use of neoadjuvant anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has not been extensively explored. The current case report highlights the notable pathological ...

Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...

In October, the FDA approved Bristol Myers’ Opdivo for resectable NSCLC and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase (ALK) rearrangements, for ...

10,12 In patients with T-cell/histiocyte-rich large B-cell lymphoma, B symptoms and hepatosplenomegaly are commonly observed. Patients with anaplastic lymphoma kinase (ALK)-positive large B-cell ...

ALK 基因突变被称为「钻石突变」，原因是合并该类突变的肺癌通常接受靶向治疗的疗效显著，预后较好。本文中，笔者分享了一则 ALK 阳性肺腺癌伴脑转移的病例，特将诊疗过程及相关知识点整理如下，旨在与各位读者交流临床经验。01简要病史患者男，30 ...

Inflammatory myofibroblastic tumors (IMTs) are known to be associated with rearrangements of the anaplastic lymphoma kinase (ALK) gene. The treatment of this type of tumor includes systemic therapies ...